AnimaBiotech
Translation Control Therapeutics, the first platform for the discovery of small molecule drugs that control mRNA translation
Translation Control Discovery Platform
Breakthrough Biology
Cloud Architecture
Proprietary Analysis
A new strategy against hard and undruggable targets
Specifically decrease or increase the production of target proteins
Translation Control Lab
Anima’s Translation Control Lab (TCL) is purpose-built for the discovery of translation modulators by integrating our proprietary technologies in biology, bioinformatics, big data image analysis and cloud software architecture
Anima Lab
Cloud
• Analysis Assessment
• Bio Data Analysis
Product Pipeline
Our pipeline programs are in Fibrosis (Collagen type I translation inhibitors), RSV (inhibiting the production of viral proteins by host cell ribosomes), Oncology (C-Myc translation inhibitors) and Huntington’s Disease (monitoring mutant Huntingtin translation pausing).
Pharma Collaborations
$30 million in upfront payments, $14 million in research funding, up to $1.05 billion in milestones and low to mid single-digit tiered royalties on sales of any Lilly products resulting from the collaboration.
For partnering inquiries, please contact partnering@animabiotech.com.
17 Scientific Collaborations
14 Publications
-
A heterogeneous tRNA granule structure exhibiting rapid, bi-directional neuritictransport
Eur J Cell Biol (2018) ; 97 : 168-179. -
Monitoring protein synthesis in single live cancer cells
Integr Biol (2016); 8 :645-53 -
DSCR1 is required for both axonal growth cone extension and steering
J Cell Biol. 2016; 23;213(4):451-62. -
In vivo single-RNA tracking shows that most tRNA diffuses freely in live bacteria
Nucleic Acid Res. (2017); 45 :926-937
Coverage
News & Events
-
2nd RNA- Targeted Drug Discovery Summit 2019
When: Dec. 3rd, 2019 - Dec. 4th, 2019
Where: Boston, USAAnima Biotech has been invited to present an overview of its Translation Control Therapeutics Platform for the discovery of small molecule drugs that control mRNA translation during the 2nd RNA- Targeted Drug Discovery Summit 2019. Yochi Slonim, Co-founder and Chief Executive Officer of Anima Biotech, will also participate with other experts as part of the “Targeting RNA with Small Molecules to Capture the Therapeutic Opportunities” panel.
With numerous approaches emerging that demonstrate genuinely viable efficacy in targeting RNA, the 2nd RNA- Targeted Drug Discovery Summit is the only industry and translational focused conference dedicated to advancing pioneering RNA targeted small molecule therapeutics. For the 2nd year, at this event KOLs and RNA pioneers join to gain a comprehensive understanding on how to translate the first generation of RNA targeted small molecules into the clinic, delve into the exciting field of epitranscriptomics and stimulate discussion on how to successfully target RNA via RNA- modifying enzymes and interfering with RNA-protein interactions.
-
Targeting RNA
When: Nov. 26th, 2019 - Nov. 27th, 2019
Where: Frankfurt, GermanyAnima Biotech has been invited to present a talk on novel targets for small molecules between transcription and translation for lung fibrosis where they will discuss the discovery of lung-specific modulators of collagen translation and give insights into its Translation Control Therapeutics Platform for the discovery of small molecule drugs that control mRNA translation during the Targeting RNA Europe Congress 2019. Dr. Iris Alroy, Vice President of R&D of Anima Biotech, will also participate in a roundtable discussion on “Discussing RNA Functionality Issues such as Selectivity, Binding, Stability and Specificity” and in the “Treating the Unmet Need: Unleashing the RNA Space With Small Molecules” panel.
The Targeting RNA Congress explores the ‘undruggable’ RNA space and showcases the latest advancements in modulation of RNA directly with small molecules and through epigenetics. The meeting brings together academic and industry leaders who are building platforms to identify and validate targets in order to assess disease relevance approaches in the RNA world.
-
BIO-Europe
When: Nov. 11th, 2019 - Nov. 13th, 2019
Where: Hamburg, GermanyAnima Biotech has been invited to present an overview of its Translation Control Therapeutics Platform for the discovery of small molecule drugs that control mRNA translation during the 25th Annual BIO-Europe International Partnering Conference.
BIO-Europe is Europe’s largest life science partnering conference offering countless opportunities to engage with global life science partners. This event features workshops and panels discussing the latest industry trends in biotech and pharma as well as company presentations and one-on-one partnering meetings.